MaaT Pharma FIRST LOOK: DSMB green light confirms MaaT033's safety in ALS phase 1

MaaT announced that the data and safety monitoring board (DSMB) recommended that the phase 1b pilot (IASO) trial of MaaT033 (microbiome therapy, oral capsule) in amyotrophic lateral sclerosis (ALS) continue without modifications after reviewing safety data in the first 8 patients. The trial will continue to enrol patients (target of 15), and data readout has slightly shifted to early 2H24 (previously 1H24). We'll be on the lookout for any signs of efficacy from the upcoming readout as this could trigger interest from potential partners for this program. We reiterate our BUY rating and € 15 TP.